Lineage Cell Therapeutics, Inc. Finance Lease, Liability, Undiscounted Excess Amount
Lineage Cell Therapeutics, Inc. (LCTX) had Finance Lease, Liability, Undiscounted Excess Amount of $2.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2022-08-11
- 2022-06-30: Finance Lease, Liability, Undiscounted Excess Amount $2.00K.
- 2019-12-31: Finance Lease, Liability, Undiscounted Excess Amount $20.00K.
- 2019-09-30: Finance Lease, Liability, Undiscounted Excess Amount $21.00K.
- 2019-06-30: Finance Lease, Liability, Undiscounted Excess Amount $26.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2022-06-30 | $2.00K 10-Q · filed 2022-08-11 |
| 2019-12-31 | $20.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $21.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $26.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |